Employees Retirement System of Texas Invests $3.09 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Employees Retirement System of Texas purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,474 shares of the biopharmaceutical company’s stock, valued at approximately $3,089,000.

Other large investors have also bought and sold shares of the company. SVB Wealth LLC acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth $27,000. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth $30,000. Ameritas Advisory Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $42,000. AlphaQuest LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $43,000. Finally, Parkside Financial Bank & Trust lifted its stake in Alnylam Pharmaceuticals by 32.6% in the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after buying an additional 44 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ALNY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. BMO Capital Markets boosted their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. JPMorgan Chase & Co. decreased their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a report on Monday, October 13th. Finally, Piper Sandler restated an “overweight” rating and issued a $489.00 price objective (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Twenty-three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $482.17.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the completion of the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the sale, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 78,328 shares of company stock worth $35,705,793. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Up 3.6%

Shares of ALNY stock opened at $445.12 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The firm has a fifty day moving average of $456.00 and a 200-day moving average of $394.23. The company has a market capitalization of $58.81 billion, a price-to-earnings ratio of -180.21 and a beta of 0.30.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.